How Do We Manage Antiaggregation in BARC I Bleeding after AMI?

Dual antiplatelet therapy (DAPT) after acute myocardial infarction (AMI) has been shown useful to reduce thrombotic events, but one of its downsides is bleeding, especially in elderly patients.

BARC bleeding type I, also called nuisance bleeding (NB), is of low frequency, but its evolution and impact remain unclear, as does its management. 

A subanalysis of the TALOS-AMI was carried out. This study included 2583 patients receiving DAPT after AMI with ASA and ticagrelor. 416 of these patients (16.1%) presented NB.

Patients presenting NB were younger (58 vs. 60 p=0.01) and showed no difference in comorbidities. Kidney function was conserved and there were no differences as regards treated vessel or number of implanted stents. 

De-escalation was from ticagrelor to clopidogrel.

At one-year followup, NB was not associated to increased BARC bleeding 2, 3, or 5 (hazard ratio [HR]‚ 1.29 [95% CI‚ 0.7–2.14]) or major cardiovascular events (HR, 1.94 [95% CI, 1.08–3.48]; P=0.026).

Read also: Valve-in-Valve Shows Good Evolution after 2 Years.

De-escalation from ticagrelor to clopidogrel reduced the incidence of bleeding compared against ticagrelor plus ASA in bleeding type I (HR‚ 0.31 [95% CI‚ 0.10–0.92]).

There was no increase in cardiovascular events at de-escalation. 

Conclusion

Nuisance bleeding (BARC type I) is frequent after AMI the first month after DAPT with ticagrelor and was associated to early bleeding. De-escalation after NB might reduce bleeding events with no increase in ischemic events. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Miembro del Consejo Editorial de SOLACI.org.

Original Title: Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.

Reference: Eun Ho Choo,e tal. Circ Cardiovasc Interv. 2022;15:e012157. DOI: 10.1161/CIRCINTERVENTIONS.122.012157.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...